US2016151443A1PendingUtilityA1

Method for medical treatment utilizing glutathione

Assignee: GAGE TERRYPriority: Sep 17, 2008Filed: Feb 9, 2016Published: Jun 2, 2016
Est. expirySep 17, 2028(~2.2 yrs left)· nominal 20-yr term from priority
Inventors:Terry Gage
A61P 37/02A61P 31/16A61P 9/10A61P 25/28A61P 17/02A61K 38/063A61K 9/0019A61P 1/18A61P 1/16
19
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method of treating a condition or conditions caused by damage to cells by a process of oxidative stress and glutathione depletion. In some exemplary embodiments, the condition or conditions may be treated by administering reduced L-glutathione to a patient through injection or intravenous infusion. In other exemplary embodiments, the condition or conditions may be treated by administering reduced glutathione monoethyl ester through injection or intravenous infusion.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of treating a condition caused by damage to cells by a process of oxidative stress and glutathione depletion, comprising:
 administering a mixture of reduced L-glutathione and reduced glutathione monoethyl ester through one of intravenous infusion or injection, wherein the ratio of reduced L-glutathione to glutathione monoethyl ester is within the range of 10:1 to 1:10, and wherein the condition is glutathione depletion.   
     
     
         2 . The method of  claim 1 , wherein the reduced L-glutathione is of the formula C 10 H 17 N 3 O 6 S. 
     
     
         3 . The method of  claim 1 , wherein the reduced glutathione monoethyl ester is of the formula C 12 H 21 N 3 O 6 S. 
     
     
         4 . A method of treating a condition caused by damage to cells by a process of oxidative stress and glutathione depletion, comprising:
 administering a mixture of reduced L-glutathione and reduced glutathione monoethyl ester through one of intravenous infusion or injection, wherein the ratio of reduced L-glutathione to glutathione monoethyl ester is within the range of 10:1 to 1:10, and wherein the condition is glutathione deficiency.   
     
     
         5 . The method of  claim 4 , wherein the reduced L-glutathione is of the formula C 10 H 17 N 3 O 6 S. 
     
     
         6 . The method of  claim 4 , wherein the reduced glutathione monoethyl ester is of the formula C 12 H 21 N 3 O 6 S.

Join the waitlist — get patent alerts

Track US2016151443A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.